Inmagene Bio
Latest round
- Series C
Last raised
- Jun 2021
Total raised
- $122M
Investors
- 9
About Inmagene Bio
Established in 2019 and based in Shanghai, China, Inmagene is a biopharmaceutical company focused on immunology-related therapeutic areas. The company also established branches in San Diego, Shanghai, Hangzhou and Wuhan. Inmagene Biopharmaceuticals has cooperated with Affibody AB, Kissei, and other enterprises. The company will be publicly listed on the Nasdaq Global Select Market under the ticker symbol "IMA". Inmagene team integrates efficient resources worldwide to develop drugs for global patients. The company is building a robust pipeline of over 10 drug candidates. Inmagene also in-licenses products for the Asia markets and, together with its partners, carries out global development activities, including multi-center clinical trials. The products of the company can be used in curing psoriasis, arthritis, ankylosing spondylitis, uveitis, and other diseases. Izokibep (IMG-020), Inmagene’s most advanced drug candidate, is about to enter the global phase 2 or 3 trials for multiple indications.
Who invested in Inmagene Bio
9 investors across 3 rounds
See all investors in Inmagene Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Inmagene Bio
Who invested in Inmagene Bio?
Inmagene Bio has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Inmagene Bio raised?
Inmagene Bio has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Inmagene Bio last raise money?
Inmagene Bio's most recent round on record is a Series C, in Jun 2021.
What does Inmagene Bio do?
Established in 2019 and based in Shanghai, China, Inmagene is a biopharmaceutical company focused on immunology-related therapeutic areas.
Where is Inmagene Bio headquartered?
Inmagene Bio is headquartered in San Diego, US.
Which VCs invest in companies like Inmagene Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Inmagene Bio's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Inmagene Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.